New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid.

<h4>Background and aims</h4>Azathioprine (AZA) is widely used for the treatment of inflammatory bowel disease (IBD) patients. AZA is catabolized by thiopurine S-methyltransferase (TPMT), which exhibits genetic polymorphisms. It has also been reported that 5-aminosalicylic acid (5-ASA) inhibits TPMT...

Полное описание

Библиографические подробности

Главные авторы:	Kazuhiko Uchiyama, Tomohisa Takagi, Yasunori Iwamoto, Norihiko Kondo, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Kamada, Kazuhiro Katada, Osamu Handa, Takeshi Ishikawa, Hiroaki Yasuda, Junichi Sakagami, Hideyuki Konishi, Nobuaki Yagi, Yuji Naito, Yoshito Itoh
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Public Library of Science (PLoS) 2014-01-01
Серии:	PLoS ONE
Online-ссылка:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0095080&type=printable
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!